Korean J Lab Med.
2003 Jun;23(3):190-198.
Antibody Responses to the Recombinant Circumsporozite Protein, Merozoite Surface Protein, and Duffy Binding
Protein Antigens of Plasmodium vivax in Korea
- Affiliations
-
- 1Department of Laboratory Medicine, College of Medicine, Kangwon National University, Chuncheon, Korea.
- 2Department of Laboratory Medicine, College of Medicine, Korea University, Seoul, Korea. kaplee@korea.ac.kr
Abstract
- BACKGROUND
Plasmodium vivax circumsporozoite protein (CSP), merozoite surface protein (MSP) and Duffy binding protein (DBP) are functionally important conserved proteins and may have an important role in developing antigens. The aim of this study was to develop recombinant CSP, MSP, and DBP antigens, to evaluate their diagnostic usefulness, and to analyze the prevalence of seroreactivity against P. vivax in five different regions in Korea. METHODS: To construct recombinant CSP, MSP, and DBP antigens from P. vivax, DNA obtained from specimens previously diagnosed as P. vivax was used. To evaluate diagnostic usefulness of recombinant CSP, MSP, and DBP antigens from P. vivax, sera from 45 patients with P. vivax and 48 normal controls including 4 patients with Plasmodium falciparum were used. For the epidemiologic study, a total of 1, 014 serum samples obtained from five different regions in Korea were used. RESULTS: The sensitivity of the IgG antibody against the P. vivax recombinant CSP, MSP, DBP antigens and the antigens mixture of these proteins were 75.6%, 62.2%, 68.9%, and 97.8%, and the specificity were 92.1%, 84.2%, 81.6%, and 97.4%, respectively. The seropositivity against P. vivax recombinant antigens was highest in Cheolwon province. The IgG seropositivity against P. vivax recombinant CSP, MSP and DBP was 2.0%, 1.2%, and 1.5%, respectively. There were no significant differences in seroreactivity against P. vivax between each recombinant protein and each five different regions in Korea. CONCLUSIONS: Newly constructed recombinant CSP, MSP and DBP were useful in the detection of antibodies against the P. vivax antigen.